Dr. Arellano's primary research focus is in the development of novel therapies for older adults with acute leukemias and myelodysplastic syndromes and immune-based therapies for hematological malignancies.
Titles and Roles
- Associate Professor, Department of Hematology and Medical Oncology
- Emory University School of Medicine
- Director, Hematology and Medical Oncology Fellowship Program
- Winship Cancer Institute of Emory University
- Research Program
- Discovery and Developmental Therapeutics
Board certified in hematology, medical oncology and internal medicine, Martha L. Arellano, MD, specializes in the treatment of leukemia, non-Hodgkin lymphoma and myelodysplastic syndromes. Dr. Arellano started practicing with Emory Healthcare in 2006.
Dr. Arellano is a clinical member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. She has served on the Winship Cancer Institute's Data Safety Monitoring Committee since 2009. She also served on Emory University's Community and Diversity Committee to develop strategies for retention and development of students and trainees.
In 2000, Dr. Arellano earned her medical degree from Emory University School of Medicine in Atlanta, Georgia. In 2001, she went on to complete her internship and in 2003 completed residency from Emory University Hospital in Atlanta, Georgia.
Dr. Arellano's areas of research interest include adoptive immunotherapy for hematopoietic malignancies and novel therapies for acute leukemia and myelodysplastic syndromes.
She is currently principal investigator on four therapeutic trials for older patients with acute myeloid leukemia and an investigator-initiated trial utilizing an immunotherapy combination for patients with leukemia who relapsed after allogeneic transplantation. She is currently working with Dr. H. Jean Khoury to develop a tissue repository for hematological malignancies, a project that has already led to several collaborations with scientists within and outside of Emory University.